Onward Therapeutics SA, a clinical stage oncology company, today announced that its French subsidiary, Onward Therapeutics France, has exercised its exclusive option and entered into a worldwide license agreement with Institut du Cancer de Montpellier (ICM), France, to further advance a breakthrough program in onco-metabolism.
English (US) ·